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Previewsviral immune evasion. The NS1 protein
of human, avian, and swine influenza A
viruses has been shown to interact with
human TRIM25 (Gack et al., 2009). This
interaction inhibits TRIM25 multimeriza-
tion and its enzymatic activity, resulting
in the abolished RIG-I ubiquitination and
host antiviral IFN response. Thus, it will
be interesting to investigate whether
NS5 or other proteins of flaviviruses
have acquired the ability of inhibiting
TRIM79a antiviral activity. Finally, as flavi-
viruses are known to adapt to different
host species, it is tempting to speculate
that evasion of TRIM antiviral restriction
factors could determine flavivirus host
adaptation and pathogenicity in the dif-
ferent hosts. Therefore, future studies
determining the interactions of flaviviralproteins with host-encoded antiviral re-
striction factors will not only shed light
on flavivirus host tropism, but may also
unveil therapeutic targets urgently needed
to treat flavivirus infections in humans.
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The HCMV-neutralizing monoclonal antibody MSL-109 failed to prevent HCMV-induced disease in the clinic.
In this issue of Cell Host & Microbe, Manley et al. (2011) found that MSL-109 rapidly induces antibody resis-
tance by a nongenetic mechanism. Their results shed light on how antibodies can interact with their targets
both outside and inside infected cells and virions.MSL-109 is a naturally occurring human
antibody that blocks human cytomegalo-
virus (HCMV) infection of many cell types
by targeting the key virion envelope
protein complex, gH/gL. In all herpesvi-
ruses, gH/gL and another glycoprotein,
gB, form the core fusion machinery that
is essential for virus-cell fusion. The crys-
tal structures of both gB and gH/gL of
HSV and EBV have been solved (Backovic
et al., 2009; Chowdary et al., 2010; Con-
nolly et al., 2011; Heldwein et al., 2006;
Matsuura et al., 2010), and it is clear
from their structures that gB is the fusion
protein, while gH/gL may serve a regula-
tory role in driving fusion, may assist gB
in fusion, or both (Atanasiu et al., 2010;
Connolly et al., 2011; Matsuura et al.,2010). Regardless, both gH/gL and gB,
as key components of the herpesvirus
entry machinery, are targets of therapies
aimed at disrupting entry. Often, anti-
bodies to these proteins can neutralize
virus.
One such antibody is MSL-109.
Because of its properties, this antibody
was chosen for clinical trials as a po-
tential therapy for HCMV disease in
AIDS patients with HCMV-induced reti-
nitis as well as in stem cell transplant
recipients. The failure of MSL-109 in
human clinical trials was a disappointing
outcome, but Manley and colleagues
(Manley et al., 2011) set out to find the
reason for the failure and discover a
surprising outcome.Indeed, Manley et al. (Manley et al.,
2011) provide convincing evidence that
HCMV rapidly develops resistance to the
effects of MSL-109 by a unique nonge-
netic mechanism. Classically, virus resis-
tance to the neutralizing effects of an
antibody develops over time. This occurs
bymutations inoneormoreproteins (often
the target of the antibody) that render
the virus insensitive to the antibody, but
still permit virus replication. However,
this turns out not to be the case for
MSL-109. The first clue was the fact that
resistance developed quite rapidly and
was readily reversible, something that is
not typical of classical resistance.
Amazingly, resistance occurs by up-
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Previewsincorporation of this antibody bound to
gH/gL into newly forming viruses at the
site of virus assembly. Thus, presentation
of the gH/gL complex on the envelope
of newly formed virions also includes
MSL-109 bound to gH/gL via its Fab
end. This means that the Fc end of
MSL-109 decorates the virion and allows
the virus to enter cells bearing a particular
class of Fc receptors, unlike the classic
Fc-g receptors on cells such as macro-
phages. Moreover, the virus loses its
ability to infect its normal target cells
such as epithelial and endothelial cells.
However, these viruses are able to infect
fibroblasts, a property of viruses that
lack the accessory proteins UL128,
UL130, and UL131. These three proteins
normally bind to gH/gL, and this complex
is required for virus entry into its normal
target cells (Ryckman et al., 2008). Thus
MSL-109 disrupts the function of the
five-protein complex. However, this effect
is reversible, suggesting that the tropism
is not altered due to a genetic change. In-
deed, Manley et al. (Manley et al., 2011)
found no mutations in gH, gL, or other
glycoproteins that would account for this
effect. Besides, resistance based on
genetic changes takes longer to develop,
as does reversion to wild-type.
Interestingly, the pathway of entry into
fibroblasts is also altered by MSL-109 so
that the virus enters via clathrin-depen-
dent endocytosis rather than by direct
fusion. It would be interesting to know
how gH (or gL) is altered to cause this
change in entry pathway as well as the
restriction of tropism. Such information
would clearly be of value in understanding
the mechanism behind both effects as
well as to gain a better understanding
of how the gH/gL-MSL-109 complex
enhances conversion of gB from a prefu-
sion to postfusion state (Atanasiu et al.,
2010; Chowdary et al., 2010). Interest-
ingly, MLS-109 does not bind to virions
in solution but still blocks virus entry.
One possibility advanced by the authors
is that it binds to a structural intermediate
formed during entry.
It has been shown that HCMV encodes
its own Fc receptors (Sprague et al.,
2008). It will be interesting to see whether
MSL-109 is taken up preferentially by one
of these receptors into infected cells and
brought to viral assembly compartments.178 Cell Host & Microbe 10, September 15, 2Furthermore, even though the naive fibro-
blasts that the MSL-109-resistant virus is
able to infect typically lack Fc-g recep-
tors, they do express the neonatal Fc
receptor (FcRn). This receptor functions
not only to transfer antibody to a devel-
oping fetus but to recycle and extend
the half-life of circulating IgG on cells
throughout the body. Perhaps it is this
form of the FcR that binds the Fc of
MSL-109 complexed to gH/gL. Under-
standing how the MSL-109 -resistant
virus uses the Fc end of MSL-109 to enter
fibroblasts may uncover a further layer of
the complex interactions of HCMV with
its host. Moreover, the precise epitope
for MSL-109 is not known, nor is it clear
if binding of MSL-109 to gH/gL physically
displaces one of the three accessory
proteins (Ul128, UL130, or UL131). In-
deed, the authors find less UL128 than is
normally found when MSL-109 is bound.
Thus, as with many great papers, this
report raises asmany important questions
as it answers.
This newly discovered method of virus-
induced escape from neutralization
(which we suggest be termed the MSL-
109 effect) adds to our understanding of
how antibodies directed at viruses can
escape virus neutralization and even force
the virus to exhibit altered tropism. The
narrowed tropism caused by virion-asso-
ciated MSL-109 is in stark contrast to the
increased tropism caused by antibodies
to other viruses. One classic example is
antibody-dependent enhancement (ADE)
of Dengue virus (Halstead et al., 1984).
In that case, however, the Fc end of a
previously formed nonneutralizing anti-
body to one virus serotype allows newly
incoming virus (usually of another sero-
type) to infect macrophages. Moreover,
in ADE, the antibody itself mediates entry
into cells expressing the classic Fc-g
receptors. In contrast, MSL-109 is a neu-
tralizing antibody, and theMSL-109 effect
allows CMV to infect fibroblasts that do
not express the classic Fc-g receptors.
On a practical clinical level, the ques-
tion then becomes, how important is
the MSL-109 effect for antibody-based
therapies for treating HCMV and other
viral diseases? Clearly, in the case of
MSL-109 itself, this mechanism may well
have prevented it from being useful in
treating HCMV disease. At the very least,011 ª2011 Elsevier Inc.promising antibodies should be checked
to be sure they do not exhibit the MSL-
109 effect. Of course, it should be noted,
as did the authors, that other naturally
occurring antibodies to HCMV do not
show this effect. Still, the story of MSL-
109 that Manley et al. (Manley et al.,
2011) have uncovered serves as a cau-
tionary tale. It underscores the impor-
tance of knowing how antibodies actually
interact with their host cells before the
decision is made to test that antibody in
clinical trials. But importantly, this dis-
covery adds to our increasing knowledge
of just how clever viruses are in their
ongoing war against host immune re-
sponses to them. Clearly, who wins this
fight depends on maintenance of a robust
immune system. One note of comfort is
that we humans are infected with as
many as eight human herpesviruses and
an increasing list of other pathogens.
That most of us remain healthy is testi-
mony to the sophistication of our own
immune armamentarium. But viruses are
clever, no doubt about it.REFERENCES
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